Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 May;267(2):560-9.
doi: 10.1148/radiol.13120118. Epub 2013 Feb 7.

MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set

Affiliations
Multicenter Study

MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set

David A Gutman et al. Radiology. 2013 May.

Abstract

Purpose: To conduct a comprehensive analysis of radiologist-made assessments of glioblastoma (GBM) tumor size and composition by using a community-developed controlled terminology of magnetic resonance (MR) imaging visual features as they relate to genetic alterations, gene expression class, and patient survival.

Materials and methods: Because all study patients had been previously deidentified by the Cancer Genome Atlas (TCGA), a publicly available data set that contains no linkage to patient identifiers and that is HIPAA compliant, no institutional review board approval was required. Presurgical MR images of 75 patients with GBM with genetic data in the TCGA portal were rated by three neuroradiologists for size, location, and tumor morphology by using a standardized feature set. Interrater agreements were analyzed by using the Krippendorff α statistic and intraclass correlation coefficient. Associations between survival, tumor size, and morphology were determined by using multivariate Cox regression models; associations between imaging features and genomics were studied by using the Fisher exact test.

Results: Interrater analysis showed significant agreement in terms of contrast material enhancement, nonenhancement, necrosis, edema, and size variables. Contrast-enhanced tumor volume and longest axis length of tumor were strongly associated with poor survival (respectively, hazard ratio: 8.84, P = .0253, and hazard ratio: 1.02, P = .00973), even after adjusting for Karnofsky performance score (P = .0208). Proneural class GBM had significantly lower levels of contrast enhancement (P = .02) than other subtypes, while mesenchymal GBM showed lower levels of nonenhanced tumor (P < .01).

Conclusion: This analysis demonstrates a method for consistent image feature annotation capable of reproducibly characterizing brain tumors; this study shows that radiologists' estimations of macroscopic imaging features can be combined with genetic alterations and gene expression subtypes to provide deeper insight to the underlying biologic properties of GBM subsets.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Screen shot shows an example of the Clear Canvas interface used for data entry.
Figure 2a:
Figure 2a:
(a) Kaplan-Meier survival curves for comparing survival rates between two dichotomized subgroups for the feature proportion contrast-enhanced tumor. (b) Kaplan-Meier survival curves for comparing survival rates between all categories.
Figure 2b:
Figure 2b:
(a) Kaplan-Meier survival curves for comparing survival rates between two dichotomized subgroups for the feature proportion contrast-enhanced tumor. (b) Kaplan-Meier survival curves for comparing survival rates between all categories.

References

    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. 4th ed. Lyon, France: International Agency for Research, 2007 - PubMed
    1. Central Brain Tumor Registry of the United States CBTRUS statistical report: primary brain and central nervous system tumors in the United States in 2004–2006. Hinsdale, Ill: Central Brain Tumor Registry of the United States, 2010
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987–996 - PubMed
    1. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011;71(12):4055–4060 - PMC - PubMed
    1. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26(10):2466–2474 - PMC - PubMed

Publication types

MeSH terms